Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianyu Sun

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Toxicology Letters|June 5, 2021
The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicityAsrin Ahmadi, Hossein Niknahad, Huifeng Li, et al.
Toxicology Letters|November 14, 2021
Corrigendum to "The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity" [Toxicol. Lett. 349 (2021)12 - 29]Asrin Ahmadi, Hossein Niknahad, Huifeng Li, et al.
Cancer Science|April 30, 2019
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibitionWenhua Liang, Minzhang Guo, Zhenkui Pan, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitorsZaihui Zhang, Vishnumurthy Kodumuru, Serguei Sviridov, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Translational Lung Cancer Research|November 19, 2020
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 casesWenhua Liang, Dan Liu, Min Li, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Toxicology Letters|June 5, 2021
The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicityAsrin Ahmadi, Hossein Niknahad, Huifeng Li, et al.
Toxicology Letters|November 14, 2021
Corrigendum to "The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity" [Toxicol. Lett. 349 (2021)12 - 29]Asrin Ahmadi, Hossein Niknahad, Huifeng Li, et al.
Cancer Science|April 30, 2019
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibitionWenhua Liang, Minzhang Guo, Zhenkui Pan, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitorsZaihui Zhang, Vishnumurthy Kodumuru, Serguei Sviridov, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Translational Lung Cancer Research|November 19, 2020
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 casesWenhua Liang, Dan Liu, Min Li, et al.
Pageof 4